佐剂
表位
结合
抗原
免疫系统
抗体
病毒学
化学
生物
免疫学
数学
数学分析
作者
Yiping Wen,Ruyan Zhang,Jian Wang,Shihao Zhou,Xiaoqian Peng,Dong Ding,Zhiming Zhang,Huawei Wei,Jun Guo
标识
DOI:10.1016/j.jconrel.2023.01.062
摘要
Self-adjuvanting protein vaccines have been proved to be highly immunogenic with efficient codelivery of adjuvant and antigen. Current protein vaccines with built-in adjuvants are all modified at the peptide backbone of antigen protein, which could not achieve minor epitope interference and adjuvant multivalency at the same time. Herein, we developed a new conjugate strategy to construct effective adjuvant-protein vaccine with adjuvant cluster effect and minimal epitope interference. The toll-like receptor 7 agonist (TLR7a) is covalently conjugated on the terminal sialoglycans of SARS-CoV-2-S1 protein, leading to intracellular release of the small-molecule stimulators with greatly reduced risks of systemic toxicity. The resulting TLR7a-S1 conjugate elicited strong activation of immune cells in vitro, and potent antibody and cellular responses with a significantly enhanced Th1-bias in vivo. TLR7a-S1-induced antibody also effectively cross-neutralized all variants of concern. This sialoglycoconjugation approach to construct protein conjugate vaccines will have more applications to combat SARS-CoV-2 and other diseases.
科研通智能强力驱动
Strongly Powered by AbleSci AI